AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11170778
Drug: Ross Ready‐to‐Hang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ross Ready‐to‐Hang containers (2 x 1000 mL rigid plastic bottles)
Trial: 8143833
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 4 mg, administered four times daily for patients on inhaled corticosteroids and twice daily for those on bronchodilator alone.
Trial: 31134640
Drug: HMB complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB complex (3 g HMB, 14 g arginine, and 14 g glutamine daily)
Trial: 31134640
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard nutrition therapy)
Trial: 31134640
Drug: HMB complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB complex (in subgroup with sequential organ failure assessment scores <10)
Trial: 31134640
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (in subgroup with sequential organ failure assessment scores <10)
Trial: 26317618
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading and 10 mg maintenance dose)
Trial: 26317618
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg reloading and 150 mg maintenance dose)
Trial: 26267731
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg at week 0, then 40 mg every other week starting at week 1)
Trial: 10988047
Drug: USPIO ferumoxtran-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO ferumoxtran-10 at a dose of 0.8 mg Fe/kg
Trial: 10988047
Drug: USPIO ferumoxtran-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO ferumoxtran-10 at a dose of 1.1 mg Fe/kg
Trial: 10988047
Drug: USPIO ferumoxtran-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO ferumoxtran-10 at a dose of 1.7 mg Fe/kg
Trial: 23800977
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg/day
Trial: 1826213
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 mg/day
Trial: 30701811
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic hepatitis C with insulin resistance (HOMA index ≥2.77)
Trial: 30701811
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic hepatitis C without insulin resistance (HOMA index <2.77)
Trial: 23280545
Drug: Saffron (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (30 mg/daily)
Trial: 20625290
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor blockers (MRBs) such as spironolactone or eplerenone, low doses added onto an angiotensin-converting enzyme inhibitor-based regimen
Trial: 20625290
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor blockers (MRBs)
Trial: 16149294
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g three times daily during radiotherapy
Trial: 16149294
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets during radiotherapy
Trial: 8521122
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of F‐CHX‐Zn
Trial: 2140488
Drug: Alfentanil continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil continuous infusion
Trial: 18978503
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) 2 g/d
Trial: 18978503
Drug: Methadone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone + Acetyl-L-carnitine (ALC) in morphine-tolerant mice
Trial: 9046194
Drug: Tannic acid
RxNorm normalized name: Tannic Acid
DrugBank: Tannic acid (DB09372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tannic acid (20%) lotion
Trial: 1326339
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 (20 mg per day during 4 weeks)
Trial: 4015388
Drug: Primary closure
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary closure with subcutaneous drains
Trial: 26988951
Drug: Continued warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued warfarin during surgery
Trial: 26988951
Drug: Empiric antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotics upon development of hematoma
Trial: 18396717
Drug: Autologous free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous free fat particle injection
Trial: 18396717
Drug: Autologous free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous free fat particle injection combined with bFGF (4,200 IU/10 mL)
Trial: 12878632
Drug: Alizapride 50
RxNorm normalized name: alizapride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride 50 mg
Trial: 26758574
Drug: Saffron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (1 g)
Trial: 26758574
Drug: Ginger (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (3 g)
Trial: 26758574
Drug: Cinnamon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (3 g)
Trial: 26758574
Drug: Cardamom (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardamom (3 g)
Trial: 18327970
Drug: Wand local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wand local anesthetic system at a deposition rate of 45 seconds (fast injection)
Trial: 18327970
Drug: Wand local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wand local anesthetic system at a deposition rate of 4 minutes and 45 seconds (slow injection)
Trial: 18327970
Drug: Conventional syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional syringe injection at a deposition rate of 4 minutes and 45 seconds (slow injection)
Trial: 15912483
Drug: Alcohol (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (average 40 mg and 28 mg alcohol/100 ml blood at the beginning and end of drive)
Trial: 1908498
Drug: Initial full
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial full dose of praziquantel followed by suppressive doses
Trial: 1908498
Drug: Initial loading
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial loading praziquantel dose followed by suppressive dose at monthly intervals
Trial: 1908498
Drug: Oral metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metrifonate therapeutic course followed by prophylactic course monthly
Trial: 1908498
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of oral praziquantel
Trial: 1908498
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of praziquantel orally every month
Trial: 1908498
Drug: Oral metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metrifonate curative course every 2 weeks for 3 doses every 6 months
Trial: 1908498
Drug: Oral monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monthly praziquantel prophylactic dose
Trial: 1908498
Drug: Praziquantel prophylactic
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel prophylactic doses at 3-monthly intervals
Trial: 1908498
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo in the form of vitamin B complex tablets at 3-monthly intervals
Trial: 1908498
Drug: Oral monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monthly therapeutic dose of metrifonate
Trial: 1908498
Drug: Oral monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monthly prophylactic doses of praziquantel
Trial: 1908498
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo in the form of 2 vitamin B-complex tablets monthly
Trial: 30413359
Drug: Tablet-based interactive
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based interactive distraction (TBID; 1 minute preseparation)
Trial: 30413359
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (15 to 45 minutes of preseparation)
Trial: 24647921
Drug: Varenicline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (titrated to 2 mg)
Trial: 8562040
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg EMD 55900
Trial: 8562040
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg EMD 55900
Trial: 8562040
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg EMD 55900
Trial: 2708742
Drug: Nicergoline (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (daily oral dose, 30 mg, and intravenous dose during dialyses, 5 mg)
Trial: 2708742
Drug: Nicergoline (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (daily dose of 30 mg for 6 months after trial)
Trial: 23124529
Drug: Exposure group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure group therapy (n = 33)
Trial: 23124529
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy (n = 32)
Trial: 21750426
Drug: Oxycodone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (15 mg, orally)
Trial: 19841125
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) therapy (initiated between 7 and 14 days of life)
Trial: 11350509
Drug: Lidocaine/prilocaine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine gel (Oraqix) applied for 30 seconds
Trial: 11350509
Drug: Lidocaine/prilocaine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine gel (Oraqix) applied for 2 minutes
Trial: 11350509
Drug: Lidocaine/prilocaine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine gel (Oraqix) applied for 5 minutes
Trial: 2558186
Drug: Pyridoxine (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (vitamin B6) 50 mg per day
Trial: 765457
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate (Monistat Cream 2%) administered once daily at bedtime for 14 days
Trial: 765457
Drug: Nystatin vaginal
RxNorm normalized name: Nystatin Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin vaginal tablets (100,000 units each) administered twice daily for 15 days
Trial: 28126581
Drug: CAMS (Collaborative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMS (Collaborative Assessment and Management of Suicidality) therapy
Trial: 28126581
Drug: Usual intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual intensive inpatient treatment (Control)
Trial: 26025994
Drug: Levalbuterol 1.25
RxNorm normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol 1.25 mg three times daily
Trial: 26025994
Drug: Albuterol 2.5
RxNorm normalized name: levalbuterol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 2.5 mg four times daily
Trial: 22978252
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of beclomethasone (BDP) 50μg and formoterol 6μg (Foster® pMDI)
Trial: 22978252
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of BDP 200μg and formoterol 24μg
Trial: 19011437
Drug: Bilastine 40
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Bilastine 40 mg
Trial: 18241919
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with thalidomide (TAD)
Trial: 18241919
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with adriamycin and dexamethasone in combination with vincristin (VAD)
Trial: 18241919
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with bortezomib (PAD)
Trial: 18241919
Drug: Post-ASCT (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-ASCT (after high-dose melphalan and autologous stem cell transplant)
Trial: 18241919
Drug: Pre-treatment levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment levels of VWF, fibrinogen and FVIII:C
Trial: 18241919
Drug: Coagulation factor
RxNorm normalized name: Coagulation factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulation factor abnormalities before and during treatment
Trial: 31437124
Drug: Aromatherapy (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (inhalation of essential oil blend)
Trial: 21045083
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg orally daily until disease progression
Trial: 21045083
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg orally daily
Trial: 15661436
Drug: Morphine exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine exposure since birth
Trial: 11873239
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous IL-2 therapy
Trial: 11873239
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous IL-2 therapy
Trial: 11873239
Drug: Subcutaneous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL-2 therapy
Trial: 11873239
Drug: All IL-2
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All IL-2 therapies
Trial: 16273644
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (Sb) 0.5 g bid PO for 6 days
Trial: 7913906
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of 250 micrograms somatostatin
Trial: 7913906
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of somatostatin after bolus injection
Trial: 27541442
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message reminders and free topical corticosteroid medication
Trial: 27541442
Drug: Standard follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard follow-up without reminders or free medication
Trial: 24894197
Drug: Selenium administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium administration
Trial: 22048460
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice daily for weeks 2-8)
Trial: 11599686
Drug: MF59-adjuvanted influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted influenza vaccine (FLU-AD; n = 204)
Trial: 11599686
Drug: Conventional subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subunit influenza vaccine (AGRIPPAL S1; n = 104)
Trial: 9844794
Drug: Pergolide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (mean final dose, 2.8 mg daily)
Trial: 9844794
Drug: Levodopa (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (mean final dose, 435 mg daily)
Trial: 7986226
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to histone (H2A-H2B)-DNA complexes in patients with scleroderma-related disorders
Trial: 7986226
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to histone (H2A-H2B)-DNA complexes in patients with systemic lupus erythematosus (SLE)
Trial: 28107765
Drug: Conventional colonoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional colonoscopy with right‐colon retroflexion (CC/R)
Trial: 20445570
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Angiotensin II receptor blocker
Trial: 20445570
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Diuretics
Trial: 18460481
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2 capsules of 1 gm per day)
Trial: 18460481
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (2 capsules of 1 gm per day)
Trial: 18460481
Drug: Hempseed oil
RxNorm normalized name: OPHIOCORDYCEPS SINENSIS 0.1 g ORAL CAPSULE [HempSeed Cordyceps]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hempseed oil (2 capsules of 1 gm per day)
Trial: 18460481
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules of 1 gm per day)
Trial: 14674902
Drug: Sitafloxacin 100
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 100 mg twice a day
Trial: 14674902
Drug: Sparfloxacin 200
RxNorm normalized name: sparfloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 200 mg day‐1
Trial: 14674902
Drug: Enoxacin 200
RxNorm normalized name: enoxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 200 mg three times a day
Trial: 14674902
Drug: Levofloxacin 100
RxNorm normalized name: levofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 100 mg three times a day
Trial: 14674902
Drug: Sitafloxacin 50
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 50 mg twice a day
Trial: 6309436
Drug: Amiloride (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (10-40 mg/day)
Trial: 6309436
Drug: MK-421 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-421 (10 mg/day)
Trial: 6309436
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg/day) plus MK-421 (10 mg/day)
Trial: 27933598
Drug: DHEP mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP mouthwash (0.103% DHEP in aqueous solution)
Trial: 27933598
Drug: diclofenac mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac mouthwash (0.074% free diclofenac in aqueous solution)
Trial: 7818568
Drug: Tenidap (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap (120 mg/day)
Trial: 7016643
Drug: Propranolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (3 mg/3 min and 0.8 mg/min)
Trial: 7016643
Drug: Phentolamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (5 mg stat and 0.5 mg/min)
Trial: 31434140
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of ketamine
Trial: 31434140
Drug: Ketamine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (various applications: intravenous, subcutaneous, intramuscular, intranasal)
Trial: 27098290
Drug: 0.1 g·kg‐1BM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g·kg‐1BM of NaHCO3
Trial: 27098290
Drug: 0.2 g·kg‐1BM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g·kg‐1BM of NaHCO3
Trial: 27098290
Drug: 0.3 g·kg‐1BM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g·kg‐1BM of NaHCO3
Trial: 23998788
Drug: Antenatal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal vitamin K1 administration (Group A)
Trial: 23998788
Drug: No antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antenatal vitamin K1 administration (Group B)